(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Ancient eggshells shed new light on crocodiles that hunted prey from trees - 2Financial plan Cordial Home Redesigns That Add Worth
- 3CDC changes kids' vaccine schedule, removing universal recommendation for some shots
- 4Book excerpt: "Enough" by Dr. Ania Jastreboff and Oprah Winfrey
- 5Iran, Hezbollah fire rockets at Israel during Passover celebrations
- Hamas urges Hezbollah to kidnap Israeli soldiers in wake of Knesset passing death penalty bill
- 8 Fundamental Stages: Novice's Manual for Secure Your Android with a VPN
- Eating Brie, Gouda, cheddar may lower dementia risk, new study says
- Well known Tea Brands for Each Tea Sweetheart
- Health insurance premiums rose nearly 3x the rate of worker earnings over the past 25 years
- China and Pakistan issue five-point peace plan for Middle East
- Kuwait is softening stance on Israel, dissident tells ‘Post’ after viral UN speech
- IDF strikes Tehran command centers, weapon production sites
- Chinese construction workers in Israel: 'I’d rather be bombed than live in poverty'
